This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Campbell, M. J. Articles by Benz, C. C. Search for Related Content PubMed PubMed Citation Articles by Campbell, M. J. Articles by Benz, C. C.

Breast Cancer Growth Prevention by Statins

¹ University of California at San Francisco Comprehensive Cancer Center, San Francisco, Califonia; ² Buck Institute for Age Research, Novato, California; ³ Clinical Proteomics Program, Food and Drug Administration-National Cancer Institute, Bethesda, Maryland; and ⁴ Wheaton College, Norton, Massachusetts

Requests for reprints: Michael J. Campbell, Department of Surgery, University of California San Francisco/Mt. Zion Medical Center, Room C342, 1600 Divisadero, San Francisco, CA 94115. Phone: 415-885-3710; E-mail: campbellm{at}surgery.ucsf.edu.

Statins are cholesterol-lowering drugs with pleiotropic activities including inhibition of isoprenylation reactions and reduction of signals driving cell proliferation and survival responses. The objectives of this study were to examine the effects of statins on breast cancer cells, both in vitro and in vivo, and to begin to determine their mechanism of action. We evaluated the effects of statins on breast cancer cell growth, phosphoprotein signaling intermediates, survival/apoptosis regulators, cell cycle regulators, and activated transcription factors. We also examined the in vivo effect of statin administration in a mouse ErbB2⁺ breast cancer model. Only lipophilic statins had direct anticancer activity in vitro. Breast cancer cells with activated Ras or ErbB2 pathways seemed to be more sensitive than those overexpressing estrogen receptor, and this correlated with endogenous levels of activated nuclear factor B (NF-B). Key intermediates regulating cell survival by NF-B activation, as well as cell proliferation by the mitogen activated protein kinase cascade, were among the earliest phosphoproteins influenced by statin treatment. These early effects were followed by declines in activator protein-1 and NF-B activation and concordant changes in other mediators of proliferation and apoptosis. In vivo results showed that oral dosing of statins significantly inhibited the growth of a mouse mammary carcinoma. Lipophilic statins can exert direct anticancer activity in vitro by reducing proliferation and survival signals in susceptible breast cancer phenotypes. Tumor growth inhibition in vivo using a clinically relevant statin dose also seems to be associated with reduced tumor cell proliferation and survival. These findings provide supporting rationale for future statin trials in breast cancer patients. (Cancer Res 2006; 66(17): 8707-13)

This article has been cited by other articles:

				A. S. Kumar, C. C. Benz, V. Shim, C. A. Minami, D. H. Moore, and L. J. Esserman Estrogen Receptor-Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1028 - 1033. [Abstract] [Full Text] [PDF]

				R. E. Teresi, S. M. Planchon, K. A. Waite, and C. Eng Regulation of the PTEN promoter by statins and SREBP Hum. Mol. Genet., April 1, 2008; 17(7): 919 - 928. [Abstract] [Full Text] [PDF]

				W. R. Farwell, R. E. Scranton, E. V. Lawler, R. A. Lew, M. T. Brophy, L. D. Fiore, and J. M. Gaziano The Association Between Statins and Cancer Incidence in a Veterans Population J Natl Cancer Inst, January 16, 2008; 100(2): 134 - 139. [Abstract] [Full Text] [PDF]

				R. Zeiser, S. Youssef, J. Baker, N. Kambham, L. Steinman, and R. S. Negrin Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity Blood, December 15, 2007; 110(13): 4588 - 4598. [Abstract] [Full Text] [PDF]

				G. A. Finlay, A. J. Malhowski, Y. Liu, B. L. Fanburg, D. J. Kwiatkowski, and D. Toksoz Selective Inhibition of Growth of Tuberous Sclerosis Complex 2 Null Cells by Atorvastatin Is Associated with Impaired Rheb and Rho GTPase Function and Reduced mTOR/S6 Kinase Activity Cancer Res., October 15, 2007; 67(20): 9878 - 9886. [Abstract] [Full Text] [PDF]

				L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey Early Breast Cancer Therapy and Cardiovascular Injury J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1435 - 1441. [Abstract] [Full Text] [PDF]

				S. Kotamraju, C. L. Willams, and B. Kalyanaraman Statin-Induced Breast Cancer Cell Death: Role of Inducible Nitric Oxide and Arginase-Dependent Pathways Cancer Res., August 1, 2007; 67(15): 7386 - 7394. [Abstract] [Full Text] [PDF]